Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SLAM DRILLS MORE COPPER MINERALIZATION AT GOODWIN (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Regenxbio Inc RGNX

Healthcare Biotechnology
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. The Company is focused on its internal development pipeline in three... see more

Recent & Breaking News (NDAQ:RGNX)

REGENXBIO Announces Presentations at the 18th Annual WORLDSymposium(TM) 2022

PR Newswire January 31, 2022

REGENXBIO Announces Initiation of Second Pivotal Trial in RGX-314 Clinical Program for the Treatment of Wet AMD Using Subretinal Delivery

PR Newswire January 10, 2022

REGENXBIO Announces FDA Clearance of IND for Clinical Trial of RGX-202, a Novel Gene Therapy Candidate for Duchenne Muscular Dystrophy

PR Newswire January 6, 2022

REGENXBIO Announces Orphan Drug Designation Granted to RGX-202, a Novel Gene Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy

PR Newswire November 22, 2021

REGENXBIO Presents Additional Positive Interim Data from Trials of RGX-314 in Wet AMD and Diabetic Retinopathy Using Suprachoroidal Delivery at AAO 2021

PR Newswire November 12, 2021

REGENXBIO Announces Closing of Eye Care Collaboration Agreement with AbbVie

PR Newswire November 9, 2021

REGENXBIO to Participate in Upcoming Investor Conferences

PR Newswire November 8, 2021

REGENXBIO Announces RGX-314 Data Presentation at the American Academy of Ophthalmology 2021 Annual Meeting

PR Newswire November 5, 2021

REGENXBIO Reports Third Quarter 2021 Financial Results and Operational Highlights

PR Newswire November 2, 2021

Pathway Development Consortium Releases Draft White Paper to Facilitate AAV Gene Therapy Development

GlobeNewswire November 2, 2021

REGENXBIO to Host Conference Call on November 2 to Discuss Third Quarter 2021 Financial Results and Recent Operational Highlights

PR Newswire October 26, 2021

REGENXBIO Presents Positive Initial Data from Phase II ALTITUDE(TM) Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery at American Society of Retina Specialists Annual Meeting

PR Newswire October 9, 2021

REGENXBIO Presents Positive Initial Data from Phase II AAVIATE® Trial of RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery and Provides Trial Update at Retina Society 54th Annual Scientific Meeting

PR Newswire October 1, 2021

REGENXBIO Announces RGX-314 Data Presentations at American Society of Retina Specialists Annual Meeting

PR Newswire October 1, 2021

REGENXBIO Announces RGX-314 Data Presentations at Retina Society 54th Annual Scientific Meeting and KOL Conference Call

PR Newswire September 27, 2021

AbbVie and REGENXBIO Announce Eye Care Collaboration

PR Newswire September 13, 2021

REGENXBIO to Participate in Upcoming Investor Conferences

PR Newswire September 7, 2021

Dr. Jean Bennett and George Migausky Join REGENXBIO Board of Directors

PR Newswire September 7, 2021

REGENXBIO Reports Second Quarter 2021 Financial Results and Operational Highlights

PR Newswire August 9, 2021

REGENXBIO to Host Conference Call on August 9 to Discuss Second Quarter 2021 Financial Results and Recent Operational Highlights

PR Newswire August 2, 2021